Literature DB >> 19193787

In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth.

Xiaoying Shen1, Robert J Parks, David C Montefiori, Jennifer L Kirchherr, Brandon F Keele, Julie M Decker, William A Blattner, Feng Gao, Kent J Weinhold, Charles B Hicks, Michael L Greenberg, Beatrice H Hahn, George M Shaw, Barton F Haynes, Georgia D Tomaras.   

Abstract

The broadly neutralizing human monoclonal antibodies (MAbs) 2F5 and 4E10, both targeting the highly conserved human immunodeficiency virus type 1 (HIV-1) envelope membrane proximal external region (MPER), are among the MAbs with the broadest heterologous neutralizing activity and are of considerable interest for HIV-1 vaccine development. We have identified serum antibodies from an HIV-infected subject that both were broadly neutralizing and specifically targeted MPER epitopes that overlap the 2F5 epitope. These MPER-specific antibodies were made 15 to 20 months following transmission and concomitantly with the development of autoantibodies. Our findings suggest that multiple events (i.e., genetic predisposition and HIV-1 immune dysregulation) may be required for induction of broadly reactive gp41 MPER antibodies in natural infection.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19193787      PMCID: PMC2663270          DOI: 10.1128/JVI.02631-08

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  30 in total

Review 1.  The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design.

Authors:  Marinieve Montero; Nienke E van Houten; Xin Wang; Jamie K Scott
Journal:  Microbiol Mol Biol Rev       Date:  2008-03       Impact factor: 11.056

2.  A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies.

Authors:  Gary Frey; Hanqin Peng; Sophia Rits-Volloch; Marco Morelli; Yifan Cheng; Bing Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-05       Impact factor: 11.205

3.  Broad HIV-1 neutralization mediated by CD4-binding site antibodies.

Authors:  Yuxing Li; Stephen A Migueles; Brent Welcher; Krisha Svehla; Adhuna Phogat; Mark K Louder; Xueling Wu; George M Shaw; Mark Connors; Richard T Wyatt; John R Mascola
Journal:  Nat Med       Date:  2007-08-26       Impact factor: 53.440

4.  In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10.

Authors:  Amapola Manrique; Peter Rusert; Beda Joos; Marek Fischer; Herbert Kuster; Christine Leemann; Barbara Niederöst; Rainer Weber; Gabriela Stiegler; Hermann Katinger; Huldrych F Günthard; Alexandra Trkola
Journal:  J Virol       Date:  2007-06-13       Impact factor: 5.103

5.  Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection.

Authors:  E S Gray; P L Moore; I A Choge; J M Decker; F Bibollet-Ruche; H Li; N Leseka; F Treurnicht; K Mlisana; G M Shaw; S S Abdool Karim; C Williamson; L Morris
Journal:  J Virol       Date:  2007-04-04       Impact factor: 5.103

6.  Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.

Authors:  M B Zwick; A F Labrijn; M Wang; C Spenlehauer; E O Saphire; J M Binley; J P Moore; G Stiegler; H Katinger; D R Burton; P W Parren
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

7.  Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C.

Authors:  James M Binley; Elizabeth A Lybarger; Emma T Crooks; Michael S Seaman; Elin Gray; Katie L Davis; Julie M Decker; Diane Wycuff; Linda Harris; Natalie Hawkins; Blake Wood; Cory Nathe; Douglas Richman; Georgia D Tomaras; Frederic Bibollet-Ruche; James E Robinson; Lynn Morris; George M Shaw; David C Montefiori; John R Mascola
Journal:  J Virol       Date:  2008-09-24       Impact factor: 5.103

8.  Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection.

Authors:  D Noah Sather; Jakob Armann; Lance K Ching; Angeliki Mavrantoni; George Sellhorn; Zachary Caldwell; Xuesong Yu; Blake Wood; Steve Self; Spyros Kalams; Leonidas Stamatatos
Journal:  J Virol       Date:  2008-11-05       Impact factor: 5.103

9.  4E10-resistant variants in a human immunodeficiency virus type 1 subtype C-infected individual with an anti-membrane-proximal external region-neutralizing antibody response.

Authors:  Elin S Gray; Penny L Moore; Frederic Bibollet-Ruche; Hui Li; Julie M Decker; Tammy Meyers; George M Shaw; Lynn Morris
Journal:  J Virol       Date:  2007-12-19       Impact factor: 5.103

10.  Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infection.

Authors:  S Munir Alam; Richard M Scearce; Robert J Parks; Kelly Plonk; Steven G Plonk; Laura L Sutherland; Miroslaw K Gorny; Susan Zolla-Pazner; Stacie Vanleeuwen; M Anthony Moody; Shi-Mao Xia; David C Montefiori; Georgia D Tomaras; Kent J Weinhold; Salim Abdool Karim; Charles B Hicks; Hua-Xin Liao; James Robinson; George M Shaw; Barton F Haynes
Journal:  J Virol       Date:  2007-10-17       Impact factor: 5.103

View more
  63 in total

1.  Identification of amino acid substitutions associated with neutralization phenotype in the human immunodeficiency virus type-1 subtype C gp120.

Authors:  Jennifer L Kirchherr; Jennifer Hamilton; Xiaozhi Lu; S Gnanakaran; Mark Muldoon; Marcus Daniels; Webster Kasongo; Victor Chalwe; Chanda Mulenga; Lawrence Mwananyanda; Rosemary M Musonda; Xing Yuan; David C Montefiori; Bette T Korber; Barton F Haynes; Feng Gao
Journal:  Virology       Date:  2010-10-30       Impact factor: 3.616

Review 2.  Is developing an HIV-1 vaccine possible?

Authors:  Barton F Haynes; Hua-Xin Liao; Georgia D Tomaras
Journal:  Curr Opin HIV AIDS       Date:  2010-09       Impact factor: 4.283

3.  Structural basis for HIV-1 neutralization by 2F5-like antibodies m66 and m66.6.

Authors:  Gilad Ofek; Brett Zirkle; Yongping Yang; Zhongyu Zhu; Krisha McKee; Baoshan Zhang; Gwo-Yu Chuang; Ivelin S Georgiev; Sijy O'Dell; Nicole Doria-Rose; John R Mascola; Dimiter S Dimitrov; Peter D Kwong
Journal:  J Virol       Date:  2013-12-11       Impact factor: 5.103

4.  Immunization with hybrid proteins containing the membrane proximal external region of HIV-1.

Authors:  Nicola Strasz; Vladimir A Morozov; Jürgen Kreutzberger; Martina Keller; Magdalena Eschricht; Joachim Denner
Journal:  AIDS Res Hum Retroviruses       Date:  2014-02-07       Impact factor: 2.205

5.  Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family.

Authors:  Mattia Bonsignori; Justin Pollara; M Anthony Moody; Michael D Alpert; Xi Chen; Kwan-Ki Hwang; Peter B Gilbert; Ying Huang; Thaddeus C Gurley; Daniel M Kozink; Dawn J Marshall; John F Whitesides; Chun-Yen Tsao; Jaranit Kaewkungwal; Sorachai Nitayaphan; Punnee Pitisuttithum; Supachai Rerks-Ngarm; Jerome H Kim; Nelson L Michael; Georgia D Tomaras; David C Montefiori; George K Lewis; Anthony DeVico; David T Evans; Guido Ferrari; Hua-Xin Liao; Barton F Haynes
Journal:  J Virol       Date:  2012-08-15       Impact factor: 5.103

6.  Broad neutralization of human immunodeficiency virus type 1 mediated by plasma antibodies against the gp41 membrane proximal external region.

Authors:  Elin S Gray; Maphuti C Madiga; Penny L Moore; Koleka Mlisana; Salim S Abdool Karim; James M Binley; George M Shaw; John R Mascola; Lynn Morris
Journal:  J Virol       Date:  2009-08-19       Impact factor: 5.103

7.  Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees.

Authors:  Pinghuang Liu; Nicole L Yates; Xiaoying Shen; Mattia Bonsignori; M Anthony Moody; Hua-Xin Liao; Youyi Fong; S Munir Alam; R Glenn Overman; Thomas Denny; Guido Ferrari; Christina Ochsenbauer; John C Kappes; Victoria R Polonis; Punnee Pitisuttithum; Jaranit Kaewkungwal; Sorachai Nitayaphan; Supachai Rerks-Ngarm; David C Montefiori; Peter Gilbert; Nelson L Michael; Jerome H Kim; Barton F Haynes; Georgia D Tomaras
Journal:  J Virol       Date:  2013-05-08       Impact factor: 5.103

8.  Cross-reactive HIV-1-neutralizing human monoclonal antibodies identified from a patient with 2F5-like antibodies.

Authors:  Zhongyu Zhu; Haiyan Rebekah Qin; Weizao Chen; Qi Zhao; Xiaoying Shen; Robert Schutte; Yanping Wang; Gilad Ofek; Emily Streaker; Ponraj Prabakaran; Genevieve G Fouda; Hua-Xin Liao; John Owens; Mark Louder; Yongping Yang; Kristina-Ana Klaric; M Anthony Moody; John R Mascola; Jamie K Scott; Peter D Kwong; David Montefiori; Barton F Haynes; Georgia D Tomaras; Dimiter S Dimitrov
Journal:  J Virol       Date:  2011-08-31       Impact factor: 5.103

9.  Autoreactivity in an HIV-1 broadly reactive neutralizing antibody variable region heavy chain induces immunologic tolerance.

Authors:  Laurent Verkoczy; Marilyn Diaz; T Matt Holl; Ying-Bin Ouyang; Hilary Bouton-Verville; S Munir Alam; Hua-Xin Liao; Garnett Kelsoe; Barton F Haynes
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-14       Impact factor: 11.205

10.  Rapid Development of gp120-Focused Neutralizing B Cell Responses during Acute Simian Immunodeficiency Virus Infection of African Green Monkeys.

Authors:  Joshua D Amos; Jonathon E Himes; Lawrence Armand; Thaddeus C Gurley; David R Martinez; Lisa Colvin; Krista Beck; R Glenn Overman; Hua-Xin Liao; M Anthony Moody; Sallie R Permar
Journal:  J Virol       Date:  2015-07-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.